Upstream Bio (NASDAQ: UPB) stock fell 23% to 47% following mixed Phase 2 VALIANT trial results for verekitug in severe asthma. 1 2 3 The 100mg q12w dose reduced annualized asthma exacerbation rate (AAER) by 56%, while the 400mg q24w dose reduced it by 39%; both statistically significant but only q12w comparable to Tezspire. 1 2 3 Trial showed lung function improvements: 122 mL FEV1 at 100mg q12w and 139 mL at 400mg q24w; verekitug well-tolerated. 1 Over 90% of eligible patients enrolled in long-term extension study; company plans Phase 3 trials in severe asthma and CRSwNP after regulatory talks. 1 2 Analysts noted mixed data met base case but fell short of best-case for less frequent dosing, leading to selloff despite positive top-line readout. 3 Sources: 1. https://www.investing.com/news/stock-market-news/upstream-bio-stock-tumbles-after-mixed-phase-2-asthma-trial-results-93CH-4499950 2. https://www.stocktitan.net/news/UPB/upstream-bio-reports-positive-top-line-resul...
- Get link
- X
- Other Apps